Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Shots:

• Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies
• The companies collaborated for the development of therapies to treat DM1
• The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Business Wire